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ABSTRACT 
 
Sexual dysfunctions (SD) occur frequently in schizophrenia patients and have a huge impact 
on quality of life and compliance. They are often associated with antipsychotic medication. 
Nicotine consumption, negative or depressive symptoms and physical illness are also 
discussed as contributing factors. Data on SD in first-episode schizophrenia patients are 
scarce. 
As part of the European First Episode Schizophrenia Trial (EUFEST), first-episode 
schizophrenia patients were randomly assigned to five medication groups. We assessed SD by 
analyzing selected items from the Udvalg for Kliniske Undersugelser (UKU) at baseline and 
five following visits.  
Differences between antipsychotics were small for all SDs and fairly little change in the 
prevalence of SDs was seen over the course of the study. A significantly larger increase of 
amenorrhea and galactorrhea was seen with amisulpride than with the other medications. In 
men, higher age, more pronounced Positive and Negative Symptom Scale (PANSS) general 
psychopathology symptoms and higher plasma prolactin levels predicted higher rates of 
erectile and ejaculatory dysfunctions. PANSS negative symptoms and higher age were 
predictors for decreased libido.  
In women, higher prolactin plasma levels were identified as a predictor of amenorrhea. 
PANSS negative symptoms predicted decreased libido. 
All evidence taken together underscores the influence of the disease schizophrenia itself on 
sexual functioning. In addition, there is a strong correlation between the prolactin-increasing 
properties of amisulpride and menstrual irregularities.
INTRODUCTION: 
 
Sexual dysfunctions (SD) are frequent in both male and female schizophrenia patients (1-3). 
As patients rarely report this problem spontaneously, it is difficult to explore. Both quality of 
life (QOL) and compliance are affected by SD (4). In a study by Olfson and colleagues (5), 
patients with SD reported poorer QOL and lower levels of enjoyment in life, were less likely 
to have a romantic partner and less satisfied with the quality of their romantic relationships. 
36% of the patients attributed changes in their sexual functions to antipsychotic medication.  
Antipsychotic treatment has frequently been associated with SD (6-9). Several mechanisms 
are discussed in this context: next to sedation due to antihistaminergic and antiadrenergic 
effects of antipsychotics or serotonergic blockade (10), low gonadal hormone levels and 
elevated prolactin may be contributing factors. Elevation of prolactin is caused by the 
antidopaminergic effect of antipsychotics in the hypothalamus (9) and has been suggested to 
impair sexual functioning via altering sex hormone release in the hypothalamic-pituitary-
gonadal axis (11). Conventional antipsychotics induce hyperprolactinemia more often than 
second generation antipsychotics, except for amisulpride, risperidone (12) and paliperidone 
(13). In addition, peripheral effects of antipsychotics on the sexual target organs need to be 
taken into account (2, 14). Clinically, a large range of SDs have been described in 
schizophrenia patients, including disturbances of sexual functioning such as erectile or 
ejaculatory dysfunction as well as disturbances of sexual experience like arousal or orgasmic 
dysfunction. 
Montejo et al. (15), in a recent study, also confirmed SD to be common in antipsychotic-
treated patients. According to this report, SD also play an important role in adherence to 
medication.  
Whether there is a causal relationship between SD and prolactin levels in schizophrenia 
patients, remains an open question. Studies addressing this issue so far have yielded divergent 
results. Canuso et al. (16) have studied women taking antipsychotics and found high rates of 
SD in normoprolactinemic and hyperprolactinemic patients. Howes et al. (3) have 
investigated patients with schizophrenia and schizoaffective disorders and reported high rates 
of SD and hypogonadism but no association between prolactin levels and sexual functioning. 
Smith et al. (17), when examining conventional antipsychotics, also failed to find a 
correlation between prolactin and SD in male patients. Only in a subgroup 
(hyperprolactinemic men), prolactin levels were negatively correlated with erectile 
dysfunction. In women, prolactin correlated negatively with libido and physical arousal 
problems.  
On the other hand, a number of groups have described an association between plasma 
prolactin and SDs. Knegtering et al. (18), when comparing sexual side effects of quetiapine 
and risperidone, indicated a higher rate of increased prolactin levels and sexual disturbances 
in patients on risperidone. They also reported significant correlations between prolactin 
elevation and SD in men. In another study by the same group (19), only 40% of emerging SD 
in schizophrenic patients were attributable to the prolactin-raising properties of 
antipsychotics. Rettenbacher et al. (20), in a drug monitoring program, found a correlation 
between diminished sexual desire and prolactin levels in male and female schizophrenia 
patients. 
Besides antipsychotics, other factors also play a role in the etiology of SD in schizophrenia, as 
it can also be observed in untreated schizophrenia patients, the main complaint being 
diminished libido (21). Contributing factors include excessive nicotine consumption, negative 
or depressive symptoms (2) and a high comorbidity with physical illness (22). 
So far, the focus of research has been on SD in chronic schizophrenia patients. Little is known 
concerning SD in first-episode patients. We have therefore explored this question by 
analyzing safety data from the European First Episode Schizophrenia Trial (EUFEST) (23, 
24). 
METHODS 
 
Results were obtained as a part of EUFEST, the methodology of which has been described in 
more detail in previous publications (23, 24). A total of 50 centres participated. Eligible 
patients were aged 18-40 years and met criteria of the Diagnostic and Statistical Manual of 
Mental Disorders (fourth edition) for schizophrenia, schizophreniform disorder, or 
schizoaffective disorder. Onset of positive symptoms had to have occurred no more than two 
years before study entry, no more than 6 weeks lifetime exposure to antipsychotics was 
allowed. 
498 patients were randomly assigned to receive haloperidol (1-4 mg/d, n=103), amisulpride 
(200-800 mg/d, n=104), olanzapine (5-20 mg/d, n=105), quetiapine (200-750 mg/d, n=104), 
or ziprasidone (40-160 mg/d, n=82). All study drugs were given orally, within the above dose 
ranges, at the treating psychiatrist’s discretion. Baseline data were collected for 
demographics, diagnoses, treatment setting, psychopathology (Positive and Negative 
Syndrome Scale [PANSS]) (25), as well as other outcome parameters described in the original 
papers. Drug safety/tolerability was assessed through direct questioning by the researcher 
using the the Udvalg for Kliniske Undersugelser (UKU) (26) as well as the St Hans Rating 
Scale (SHRS) (27), for extrapyramidal adverse events. Furthermore, a physical examination 
was done in all patients; laboratory data (prolactin among other parameters) were recorded 
and an electrocardiogram (ECG) was obtained. The study lasted 52 weeks during which 
patients were seen at baseline, 2, 4, 6, 8 and 12 weeks later and in 3 monthly intervals from 
then on. 
SDs were assessed by analyzing selected items from the UKU at baseline and after 1, 3, 6, 9 
and 12 months of medication. The UKU Side Effect Rating Scale comprises a total of 48 
symptoms. Out of these, the following items were used for this analysis: menorrhagia, 
amenorrhea, galactorrhea, gynaecomastia, increased sexual desire, diminished sexual desire, 
erectile dysfunction, ejaculatory dysfunction, orgastic dysfunction, dry vagina. For each 
symptom, scores on the severity scale range from 0-3. Laboratory parameters were assessed at 
baseline and after 6 and 12 months. 
 
 
Statistical methods 
Two different methods were used to analyze the prevalence of the individual SDs 
(dichotomized into present vs. absent, UKU scores either 0 (SD absent) vs. >= 1 (SD present)) 
over the course of time:  
1) A simple comparison of SDs at baseline and at the end of treatment (12 months) using the 
last-observation-carried-forward (LOCF) method for missing value replacement. This analysis 
involved the Chi-square test for a baseline comparison of the five antipsychotics with regard 
to the individual SDs, the McNemar test for an analysis of the SDs over the course of time 
(baseline vs. end of treatment) and ordinal logistic regression for comparing the individual 
antipsychotics with respect to changes of SDs from baseline to end of treatment. For 
comparison, the same analyses were also performed for observed cases (OC). 
2) A comprehensive longitudinal data analysis of the individual SDs using generalized 
estimation equations (GEE) logistic regression assuming an autoregressive correlation 
structure in the course of time (28). Independent variables considered in this analysis were 
antipsychotic treatment (5-level factor: 5 antipsychotics), time (6-level factor: 0, 1, 3, 6, 9 and 
12 months) and time-by-treatment interaction. In order to limit the degrees of freedom and to 
maintain an appropriate level of statistical power, the factor time was dichotomized into 
baseline and post-baseline for analyzing the time-by-treatment interaction. In order to identify 
differential treatment effects that may be overlooked when inspecting only the time-by-
treatment interaction, the above analysis was performed a second time using post-baseline 
observations only, adjusting for baseline SD as a covariate. In this case, a significant main 
effect of the factor “antipsychotic” indicates genuine treatment differences unaffected by 
potential baseline differences. Post-hoc treatment comparisons were carried out when the 
treatment effect or the time-by-treatment interaction was statistically significant; both the least 
significant difference (LSD) method and the Bonferroni method were used. 
In order to explore the effect of factors other than antipsychotic medication on the prevalence 
of SDs, we additionally performed longitudinal GEE logistic regression analyses for the 
individual SDs considering the following variables as potential predictors: age, 
psychopathology (PANSS subscales for positive, negative and general symptomatology), 
prolactin level and the use of potentially prolactin-increasing comedications (yes/no). All of 
these variables except age were modeled as time-dependent covariates. The backward 
stepwise elimination method was used for variable selection. All statistical tests were 
performed at a 0.05 level of significance. 
 
 
RESULTS 
 
Prevalence rates of SDs in general 
Prevalence rates of SDs in male and female subjects are shown in Table 1, both at baseline 
and at 12 months (end of treatment). As differences between the individual antipsychotics 
were small for all SDs (there were neither significant treatment main effects nor significant 
baseline differences between APs) prevalence rates for the individual APs were pooled. 
Significant interactions between antipsychotics and time were observed for two SDs and will 
be dealt with in more detail below. 
Overall, fairly little change in the prevalence of SDs was seen over the course of the study. In 
men, the prevalence of increased libido was found to diminish with time. In women, the 
prevalence of galactorrhea showed a significant increase. However, the highly significant 
interaction between time and antipsychotic (p=0.001) indicates that there was considerable 
heterogeneity among the individual drugs regarding the time course of galactorrhea. A similar 
heterogeneity was also observed for amenorrhea. In both cases a significantly stronger 
increase of SDs was seen with amisulpride than with the other medications (details in Table 
1). A closer inspection of the time-by-treatment interaction for these two SDs is discussed in 
the following and detailed in table 2. No other SD in women showed a significant change over 
the course of time.  
Modifications of the statistical analysis did not greatly affect these findings. When replacing 
the LOCF analysis by an analysis without imputation of missing values, the time-by-treatment 
interaction remained significant for galactorrhea (24 = 14.2, p=0.007) and almost significant 
for amenorrhea (24 = 9.0, p=0.060). When substituting the simple comparison of baseline and 
12 months assessment by an analysis of the entire time course of the SD (using GEE logistic 
regression analysis), only one further SD was found to show a significant change over time, 
namely decreased libido in men (30.8% at baseline, 37.5% at 3 months, dropping to 27.4% at 
12 months, 25 = 13.5, p=0.015). However, this finding does not withstand a Bonferroni 
correction for multiple testing and thus the possibility of a chance finding cannot be ruled out. 
 
Time course of amenorrhea and galactorrhea – comparison of the individual antipsychotics 
Table 2 provides a detailed analysis of the time course of amenorrhea and galactorrhea, i.e. of 
the two SDs which had shown differential treatment effects. When considering the individual 
antipsychotics separately, significant changes over time of both amenorrhea and galactorrhea 
were seen in women receiving amisulpride, but not for any other drug. Significantly higher 
rates of amenorrhea, compared to baseline, were found after 3 and 6 months of treatment with 
amisulpride. Similarly, a significant increase in the prevalence of galactorrhea was observed 
after 3 months of treatment with amisulpride. Trend level significance (p<0.07) was also seen 
after 1, 6 and 12 months. 
These findings were largely confirmed by GEE logistic regression analysis. For amenorrhea, 
the time-by-treatment interaction did not reach statistical significance. However, the main 
effect of the factor “antipsychotic” considering only post-baseline observations attained 
significance (p=0.037), confirming the presence of treatment differences regarding the 
prevalence of amenorrhea. Pairwise comparisons showed significantly higher rates of 
amenorrhea with amisulpride than with haloperidol, olanzapine or ziprasidone.  
For galactorrhea, a significant time-by-treatment interaction was found, revealing a different 
time pattern of this SD for the individual antipsychotics. Post-hoc comparisons between drugs 
demonstrated higher rates of galactorrhea with amisulpride than with all other medications. 
No differences were observed between the other antipsychotics. 
 
Effect of age, psychopathology and prolactin level on the prevalence of SDs 
Demographic data and ranges of laboratory markers are described in detail in the original 
paper. Of relevance for the results reported here are the mean age of 26 years with an age 
range of 18.1-40.0 years, and prolactin levels ranging between 0.04-8.58 U/l with average 
levels of 0.70 U/l in men and 1.59 U/l in female patients. In order to explore the effect of 
factors other than antipsychotic medication on the prevalence of SDs, we performed GEE 
logistic regression analyses based on the data of all assessment times. Results are presented in 
Table 3. In men, higher age, more pronounced PANSS general psychopathology symptoms 
and higher plasma prolactin levels significantly predicted higher rates of both erectile and 
ejaculatory dysfunctions. Higher PANSS positive symptom scores were found to predict 
higher rates of increased libido, whereas more PANSS negative symptoms and higher age 
were identified as predictors of decreased libido. Higher age and more pronounced PANSS 
general symptoms predicted higher rates of orgastic dysfunction. 
In women, PANSS positive symptoms were found to predict higher rates of menorrhagia. 
Higher prolactin plasma levels were identified as a predictor of amenorrhea, whereas none of 
the variables tested was found to significantly predict galactorrhea. Like in men, more 
pronounced PANSS negative symptoms predicted decreased libido and, at a trend level, 
PANSS positive symptoms predicted increased libido. Unlike the situation in men, none of 
the variables tested significantly predicted orgastic dysfunction in women. 
The use of co-medications with a potential impact on prolactin levels or sexual functioning 
was also considered as a potential predictor but did not attain statistical significance for any of 
the SDs. 
As the incidence of diabetes in EUFEST was very low, statistical analyses concerning the 
possible influence of metabolic adverse events on SDs could not be performed. 
 
 
DISCUSSION 
 
The prevalence of SD in schizophrenia patients has been shown to be high in all well-
designed previous reports (1-9). Unfortunately, the elucidation of causative factors remains 
challenging. With the exception of amenorrhea and galactorrhea, we did not find a significant 
difference in SDs between the different antipsychotics studied in EUFEST. Compared to most 
other studies, the rates of SDs were somewhat lower in our sample of first-episode patients. In 
support of this, van Bruggen et al. (29) have reported similar rates of SD at baseline in a 
sample of first episode patients, consisting mainly of males. We found little change from 
baseline over the observed time span. This is in contrast to findings of other groups, which 
have examined chronic schizophrenia patients. Montejo and colleagues (30), for example, 
have described quetiapine to improve SD in chronic schizophrenia patients over the course of 
6 months in a naturalistic setting.  
Other groups have also assessed the frequency of sexual disturbances, albeit with somewhat 
less rigorous methodology, as for instance relying on spontaneous reports of SDs, which is 
likely to underestimate their true prevalence, given the reluctance of both patients and doctors 
to discuss sexuality. Hanssens and colleagues (31) found aripiprazole to reduce SDs to a 
larger extent than olanzapine, quetiapine or risperidone in a large open label switching study. 
This went hand in hand with a decrease of prolactin in aripiprazole-treated patients.  
Rossi and colleagues (32) showed that switching schizophrenia patients from various 
antipsychotics to ziprasidone improved not only psychopathological symptoms, but also SD, a 
finding which was corroborated by a study carried out by Montejo et al. (33), who also 
reported that switching to ziprasidone is associated with a normalization of sexual function. A 
large multicenter study by Dossenbach and colleagues (34) suggested clinically relevant 
differences in the sexual side effect profiles of haloperidol, risperidone, olanzapine and 
quetiapine. Treatment with olanzapine and quetiapine led to less SD (measured by UKU) 
when compared to risperidone or haloperidol. Females on olanzapine or quetiapine reported a 
lower rate of menstrual irregularities than those on risperidone or haloperidol. The 
discrepancy to our results - we did not find a higher rate of menstrual irregularities in the 
haloperidol group - could be attributed to the fact that the haloperidol dose used in their study 
was considerably higher (on average 11.9 mg/d in contrast to 3 mg in EUFEST). Also, one 
needs to consider that theirs was an open observational study without random treatment 
assignment. 
Using a more rigorous measurement, namely the Psychotropic-Related Sexual Dysfunction  
Questionnaire (PRSexDQ- SALSEX) (35), Montejo and colleagues (36) found aripiprazole to 
improve SD in schizophrenic patients, both in patients taking it as their first antipsychotic as 
well as in those switched to it from another drug. 
Given the small difference in SDs from baseline to endpoint in our study, one could assume a 
greater influence of the disease itself, as also underscored by the correlations between SDs 
and PANSS scores.  
We found that the item “increased libido” decreased significantly over the course of time in 
men. As higher PANSS positive subscores predicted increased libido, this relationship is 
likely to reflect effective antipsychotic treatment. One could speculate that this is due to an 
amelioriation of specific symptoms such as for instance delusions of grandeur or an increase 
of drive. 
In women, galactorrhea increased over the observation period. Our analysis shows, that this 
can be attributed to amisulpride, which led to a significantly higher likelihood of galactorrhea, 
when compared to the other antipsychotics. A differential risk could also be found with 
respect to amenorrhea in amisulpride-treated patients, in whom we found a stronger effect 
than in patients on haloperidol or olanzapine. The galactorrhea- and amenorrhea-inducing 
properties of amisulpride are well known (37, 38) and are attributed to hyperprolactinemia. A 
closer look at the time course (table 2) shows a marked increase after 3 and 6 months. In 
contrast to the rather stable rates of galactorrhea from month 3 until the end of the observation 
period, amenorrhea rates showed a certain decrease after the peak at month 6. However, as 
this decrease was not statistically significant, it may well be due to random fluctuation only 
and should therefore not be overrated. 
The influence of prolactin levels on SD is still discussed controversially. In our study, higher 
prolactin levels predicted ejaculatory dysfunction and – at a trend level - erectile dysfunction. 
Hummer et al. (39) have compared haloperidol- and clozapine-treated patients and found little 
difference in the incidence of sexual disturbances in patients on these medications in the long 
term. Although prolactin was not measured in this study, it indirectly supports the notion that 
prolactin levels are not the major driving force behind antipsychotic-induced sexual problems 
as clozapine, in stark contrast to haloperidol, has no sustained influence on prolactin levels. 
Yet, there is also evidence for less sexual dysfunction on clozapine than on other 
antipsychotics (40, 41). Van Bruggen and colleagues (29) concluded that SDs in patients with 
first episode psychosis can occur despite normal prolactin levels. Konarzewska and 
colleagues (42) described risperidone to elicit a higher prolactin elevation than olanzapine and 
associated this with lowered levels of testosteron and FSH. Patients receiving risperidone 
showed higher level of sexual dysfunction and treatment non-adherence than those treated 
with olanzapine. 
When reviewing the research on the association between plasma prolactin and disturbances of 
sexual experience and function, one is struck by the inconsistency of findings. All evidence 
taken together one can conclude that it is highly unlikely that prolactin elevation is the sole 
cause of SD. Other neurobiological causative factors, including peripheral effects of 
antipsychotics on sexual target organs must also be appreciated. It is interesting that no SDs 
occur in women with idiopathic hyperprolactinemia, who are substituted with oestrogen, 
which suggests that hypogonadism, which has been found long before the introduction of 
antipsychotics (43), must also be considered. In contrast to the inconsistent effects on SDs, a 
close connection between the prolactin-increasing properties of amisulpride and menstrual 
irregularities is very likely, as substantiated in our study. 
All patient groups showed a high prevalence of hyperprolactinemia at baseline. Whether or 
not patients were antipsychotic-naïve or had received any other medication prior to study 
entry had no influence (data not shown). Next to prolactin-producing tumors, which can be 
ruled out in our sample, various physiological factors may have contributed to 
hyperprolactinemia. Different types of stress and sleep disturbances can lead to an increase of 
prolactin levels (44). As patients in our study were acutely ill, psychotic stress and/or 
agitation may have led to prolactin increase. Extreme physical exercise, as sometimes 
performed by psychotic patients, has also been suggested as a possible cause (45).  
 
Clearly, non-pharmacologic variables also have an impact on the sexuality of schizophrenia 
patients. In men, a high PANSS general psychopathology score was a predictor for a higher 
rate of erectile, ejaculatory and orgastic dysfunction. Age was a negative predictor for orgastic 
dysfunction. As the latter finding is what one would intuitively expect, it can also be seen as 
an internal indicator for the validity of the SD assessment used in this study. Higher PANSS 
positive subscores predicted increased libido, which decreased over time in relation to 
symptom improvement. This indicates an association between psychopathological symptoms 
and sexual performance in men. In female patients (like in men), a high PANSS negative 
subscore predicted decreased libido. This is in contrast to Fan and colleagues (46), who found 
higher scores on the PANSS positive subscale to be significantly associated with more 
difficulty in both sexual arousal and orgasm in women but have not reported a connection 
between PANSS negative scores and decreased libido. This may well be explained by a 
considerably smaller sample studied by this group. Westheide and colleagues (47) found an 
association between SD and subjective well-being in risperidone-treated patients, 
emphasizing the clinical relevance of sexual functioning in schizophrenia and its potential 
influence on compliance behaviour, as also discussed by Montejo et al. (15). 
 
In summary, our findings indicate that SD in first-episode schizophrenia patients is a common 
problem, as shown by its prevalence and chronicity. These adverse events were fairly evenly 
distributed between the five antipsychotics administered while patients on amisulpride 
presented with a clearly higher risk for amenorrhea and galactorrhea. Psychopathology and 
age also contributed to SD.  
As sexual experiences are vulnerable to subjective interpretation, the open-label, although 
randomized, design of our study must be taken into account when evaluating the reported 
data. Furthermore, the UKU is a general adverse event scale which has not been specifically 
validated to assess SD in schizophrenia patients. Future studies should employ more specific 
rating scales like the aforementioned PRSexDQ- Salsex. Unfortunately, we also have no 
information about pretreatment sexual activity of our patient sample. We also have not 
collected information regarding the subjective relevance of SD. Lastly, the difficulties of 
assessing sexual functioning in general and more specifically in schizophrenia patients need 
to be acknowledged. 
Despite these potential limitations, this study is the first to report on a large, unselected 
sample of first-episode schizophrenia patients, about 30% being drug-naïve. All schizophrenia 
patients had a recent onset of the disorder, so that the debilitating effects of chronic 
schizophrenia could not yet have materialized. As first encounters with psychiatric institutions 
including the positive and negative effects of medication are known to shape future attitudes 
and the therapeutic alliance, this is a group of patients deserving special attention with respect 
to satisfaction with their sexual lives. 
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Table 1 Prevalence of sexual dysfunctions in male and female patients: baseline vs. 12 months (end of treatment) 
 
 
   Prevalence of SD (UKU score  1) 
all APs pooled 
 Statisticsa 
   Baseline 12 months 
(LOCF) 
 Time (baseline vs. 
12 months) 
 Time (baseline vs. 12 m) 
x AP 
Sexual dysfunctions in men        
  Gynaecomastia   1.3 % 4.2 %  p=0.065   n.s. 
  Erectile Dysfunction   17.7 % 16.9 %  n.s.  n.s.
  Ejaculatory Dysfunction    15.7 % 12.3 %  n.s.  n.s.
  Increased Libido    7.1 %  2.1 %  p=0.017  n.s.
  Decreased Libido    30.8 % 27.4 %  n.s.  n.s.
  Orgastic Dysfunction  15.0 % 11.9 %  n.s.  n.s.
        
Sexual dysfunctions in women        
  Menorrhagia  5.7 % 3.4 %  n.s.  n.s. 
  Amenorrhea  11.9 % 9.1 %  n.s.  24=14.3, p=0.006 b 
  Galactorrhea  1.1 % 5.1 %  p=0.039  24=18.6, p=0.001 c 
  Dry vagina  4.7 % 7.5 %  n.s.  n.s.
  Increased Libido    8.2 % 5.2 %  n.s.  n.s.
  Decreased Libido    27.5 % 25.3 %  n.s.  n.s.
  Orgastic Dysfunction  11.3 % 17.9 %  n.s.  n.s.
a Analysis by Mc Nemar test (column “Time”) and by ordinal logistic regression on changes in sexual dysfunctions (column “Time x AP”)  
b Analysis or treatment contrasts indicates significantly stronger increase of amenorrhea with Amisulpride than with Haloperidol or Olanzapine (2 > 7.0, p<0.01) 
c Analysis or treatment contrasts indicates significantly stronger increase of galactorrhea with Amisulpride than with Olanzapin, Quetiapine or Ziprasidone (2 > 6.0, p0.014) 
SD=sexual dysfunction, AP=antipsychotic, LOCF=last observation carried forward, n.s. = not significant (p > 0.1) 
 
Table 2: Prevalence of amenorrhea and galactorrhea over the course of time 
 
  Randomized study medication (AP) 
Statistics (Generalized estimating equations logistic 
regression) 
   Haloperidol Olanzapine Quetiapine Amisulpride Ziprasidone  Effect a 2/d.f. p-value 
           
Amenorrhea           
Baseline 19.4% 15.8% 18.2% 6.5% 2.6%  Time  12.98/ 5 0.024 
1 month 21.9% 21.1% 20.6% 17.4% 11.8%  AP  7.03/ 4 0.134 
3 months 20.7% 13.5% 22.9% 28.2%  6.1%  Timeb x AP 6.31/ 4 0.177 
6 months 4.0% 14.3% 22.6% 35.3%  10.3%  AP without baselinec 10.19/ 4 0.037 
9 months 9.1% 9.1% 17.9% 20.6% 10.3%     Amisulpride vs. Haloperidol 6.35/ 1 0.012 
12 months 0.0% 5.9% 14.3% 18.2% 3.6%     Amisulpride vs. Olanzapine 5.67/ 1 0.017 
          Amisulpride vs. Ziprasidone 3.92/ 1 0.048 
           
Galactorrhea          
Baseline 2.8% 0.0% 0.0% 0.0% 5.3%  Time  6.87/ 5 0.230 
1 month 6.3% 0.0% 0.0% 10.9% () 5.9%  AP 19.21/ 4 0.001 
3 months 3.4% 0.0% 5.9% 17.9%  0.0%  Timeb x AP 12.72/ 4 0.015 
6 months 8.0% 2.9% 3.2% 14.7% () 3.4%     Amisulpride vs. Haloperidol 5.79/ 1 0.016 
9 months 4.5% 0.0% 3.6% 11.8% 3.4%     Amisulpride vs. Olanzapine 7.71/ 1 0.005d 
12 months 7.7% 0.0% 0.0% 15.2% () 0.0%     Amisulpride vs. Quetiapine 5.81/ 1 0.016 
          Amisulpride vs. Ziprasidone 9.42/ 1 0.002d 
a  This column contains the main effects and interaction terms used in the GEE logistic regression analysis as well as the statistically significant time-by- 
   treatment contrasts (galactorrhea) or post-baseline treatment contrasts (amenorrhea) evaluated by the least-significant-difference (LSD) method 
b  Time was dichotomized into baseline vs. post-baseline (see Statistical Methods section) 
c Analysis of post-baseline observations only, with adjustment for baseline value (see Statistical Methods section) 
d  Statistical significance is maintained after Bonferroni correction for multiple comparisons 
 Significantly higher than at baseline using McNemar’s test, p<0.05  [ () p < 0.07 ]  
AP=antipsychotic, GEE= Generalized estimating equations, d.f. = degrees of freedom  
 
Table 3: Effect of age, psychopathology and prolactin level on sexual dysfunctions: Results of GEE logistic regression analysis  
 
 
Gender Sexual dysfunction  Predictor 
    Age PANSS pos.  PANSS neg.  PANSS general Prolactin level ( ln) 
Male Gynaecomastia  n.s. n.s. n.s. n.s. n.s. 
 Erectile Dysfunction    = 0.080, ² = 12.6 
p<0.001 
n.s. n.s. =0.015, ² = 5.5  
p=0.019 
 =.249, ² = 3.7  
p=0.053 
 Ejaculatory Dysfunction   = 0.060, ² = 5.5, 
p=0.019 
n.s. n.s.  = 0.015, ² = 4.9 
 p=0.027 
 = 0.296, ² = 4.3 
p=0.038 
 Increased Libido    n.s.  = 0.081, ² = 18.2 
p<0.001 
n.s. n.s. n.s. 
 Decreased Libido     = 0.076, ² = 16.1 
p<0.001 
n.s.  = 0.047, ² = 22.4 
p<0.001 
n.s. n.s. 
 Orgastic Dysfunction   = 0.072, ² = 8.4 
p=0.004 
n.s. n.s.  = 0.014, ² = 3.8  
p=0.050 
n.s. 
Female Menorrhagia  n.s.  = 0.057, ² = 5.9 
p=0.015 
n.s. n.s. n.s. 
 Amenorrhea  n.s. n.s. n.s. n.s.  = 0.49, ² = 5.9  
p=0.015 
 Galactorrhea  n.s. n.s. n.s. n.s. n.s. 
 Dry vagina  n.s. n.s. n.s. n.s. n.s. 
 Increased Libido    n.s. ( = 0.039, ² =2.8, 
p=0.093) 
n.s. n.s. n.s. 
 Decreased Libido    n.s. n.s.  = 0.040, ² = 9.6
 p=0.002 
n.s. n.s. 
 Orgastic Dysfunction  n.s. n.s. n.s. n.s. n.s. 
GEE= Generalized estimating equations, PANSS = Positive and Negative Syndrom Scale, n.s. = not significant (p> 0.1) 
